The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1261 articles
As New Zealand considers public funding for Wegovy, experts warn that medication alone cannot solve the obesity epidemic driven by complex environmental and social factors.
Glenmark Pharmaceuticals outlines an ambitious FY27 growth strategy, highlighting significant expansion in the GLP-1 segment with GLIPIQ. Discover how this impacts global access to Semaglutide and weight loss therapies.
New data from EPIC Research highlights a correlation between rising GLP-1 prescriptions and a modest decline in US obesity rates, offering hope amidst ongoing challenges.
Novo Nordisk's revolutionary Wegovy pill (oral semaglutide) is set to transform weight management in the UAE. Discover the details of its early access launch, clinical benefits, and how it integrates into advanced care pathways.
A groundbreaking study utilized AI to sift through over 400,000 Reddit posts, uncovering potential new side effects associated with popular GLP-1 medications such as Ozempic, Wegovy, and Mounjaro. This research highlights the growing role of real-world data in understanding medication safety.
GLP-1 agonists, famously known for Ozempic and Wegovy, are making waves beyond their initial indications. While weight loss and diabetes management remain key, researchers are uncovering a broader therapeutic potential for these powerful peptide therapies.
Once a distant rumor, the idea of widespread obesity in America is now being challenged by a new wave of medications. Discover how GLP-1 drugs are changing the landscape of weight management and what it means for public health.
Australia has released a groundbreaking clinical consensus statement on obesity and cardiovascular disease (CVD), marking a pivotal moment in medical practice. This new guidance places GLP-1 receptor agonists—a class of medications including semaglutide and tirzepatide—at the forefront of treatment strategies, offering clinicians a clear, practical pathway for improving patient outcomes.
While BMI is a primary factor, a range of underlying health conditions and personal histories can lead to a doctor declining a prescription for popular weight loss medications like Mounjaro and Wegovy. Understanding these criteria is vital before seeking treatment.
